Search Results for "Oncology"

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.

A new analysis reviews several analyses of differential costs of care provided in the doctors office and hospital outpatient settings.

Lynne Lederman reports on the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

Members of Congress provided conflicting forecasts on how the agency's proposed pilot program of Part B drug payment might affect aspects of Medicare beneficiary care.

Peter Bach speaks about the Drug Abacus, the importance of using value frameworks, and using the European market as a model to recalibrate the healthcare system in the United States.

Oral anticancer agents are being launched at significantly higher prices compared with a decade ago and has become a barrier for some patients.

A new analysis sheds light on why proposed changes to the system are being met with opposition and what they could mean for providers and patients.

Infusion of chemotherapy has long been a profit center for medical oncologists. Here are various approaches to cancer drug payment reform, and their strengths and weaknesses.